可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Zilla P, Brink J, Human P. Prosthetic heart valves: Catering for the few[J]. Biomaterials, 2008, 29(4):385-406.
[2] Krahn AD, Healey JS, Simpson CS, et al. Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: wide variability of perioperative bridging in Canada[J]. Heart Rhythm, 2009, 6(9):1276-1279.
[3] Ennker JA, Ennker IC, Albert AA, et al. Florath I.The Freestyle stentless bioprosthesis in more than 1000 patients: a single-center experience over 10 years[J]. J Card Surg, 2009, 24(1):41-48.
[4] Borger MA, Carson SM, Ivanov J, et al. Stentless aortic valves are hemodynamically superior to stented valves during midterm follow-up: a large rest respective study[J]. Ann Thorac Surg, 2005, 80(6):2180-2185.
[5] Pavoni D, Badano LP, Ius F, et al. Limited long-term durability of the Cryolife OBrien stentless porcine xenograft valve[J]. Circulation, 2007, 116 (11 Suppl):I307-I313.
[6] Gross JM.Calcification of bioprosthetic heart valve and its assessment[J]. J Thorac Cardiovasc Surg, 2001, 121(3):428-430.
[7] Eberl T, Siedler S, Schumacher B, et al. Experimental in vitro endothelialization of cardiac valve leaflets[J]. Ann Thorac Surg, 1992, 53(3):487-492.
[8] 易定华,刘维永,王伯云,等. 减轻异种(猪)主动脉瓣钙化的实验研究[J]. 中华胸心血管外科杂志, 1988, 4(1):48-51.
[9] 易定华,刘维永. 生物心脏瓣膜钙化机理及抗钙化研究[J]. 中华外科杂志, 1996, 34(10):631-633.
[10]Trowbridge EA, Lawford PV, Crofts CE, et al. Pericardial heterografts: Why do these valves fail?[J]. Thorac Cardiovasc Surg, 1988, 95(4):577-585.
[11]Jamieson WR, Janusz MT, MacNab J, et al. Hemodynamic comparison of second- and third-generation stented bioprostheses in aortic valve replacement[J]. Ann Thorac Surg, 2001, 71(5 Suppl):S282-S284.
[12]Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study[J]. Circulation, 2006, 114(15):1616-1624.
[13]Wenaweser P, Buellesfeld L, Gerckens U, et al. Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system[J]. Catheter Cardiovasc Interv, 2007, 70(5):760-764.
[14]Webb JG. Percutaneous aortic valve replacement will become a common treatment for aortic valve disease[J]. JACC Cardiovasc Interv, 2008, 1(2):122-126.
[15]Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model[J]. Ann Thorac Surg, 1995, 60 (6 Suppl):S513-S516.
[16]Hoerstrup SP, Kadner A, Melnitchouk S, et al. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells[J]. Circulation, 2002, 106 (12 Suppl):I143-I150.
[17]顾春虎,刘维永.去细胞支架材料构建组织工程心脏瓣膜研究进展[J]. 心肺血管病杂志, 2005, 24(4):247-249.
[18]Dohmen PM, Lembcke A, Holinski S, et al. Mid-term clinical results using a tissue engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure[J]. Ann Thorac Surg, 2007, 84(3):729-736.
[19]Dong X, Wei X, Yi W, et al. RGD-modified acellular bovine pericardium as a bioprosthetic scaffold for tissue engineering[J]. J Mater Sci Mater Med, 2009, 20(11):2327-2336.
[20]Gu CH, Zhen RH, Yang ZF, et al. Novel glycidyl methacrylated dextran/gelatin nanoparticles loaded with basic fibroblast growthfactor:formulationand characteristics[J]. Drug Development and Industrial Pharmacy, 2009, 35(12):1419-1429.
[21]Wu X, Wei X, Gu C, et al. Optimisation of Dex-GMA nanoparticles prepared in modified micro-emulsion system: Physical and biologic characterization[J]. J Biotechnol, 2009, 143(4):268-273.
[22]顾春虎,易定华,王云雅,等. 动态仿生脉动反应器: 中国实用新型专利200802216284[P]. 2008-02-21.
[23]Liu Y, Liu W, Sun G, et al. Calcification resistance of procyanidin-treated decellularized porcine aortic valves in vivo[J]. Heart Surg Forum, 2009, 12(1):E24-E29.
[24]顾春虎,王云雅,易定华,等. 内皮祖细胞和去细胞猪主动脉瓣构建组织工程瓣膜的研究[J]. 中华实验外科杂志, 2007, 24(3):263-264.